All In Biotech

Drug Trial Radar · NCT02403674

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 734 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

734

Actual

Start

Jun 5, 2015

Primary completion

Mar 20, 2017

Study completion Sep 7, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 31, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439A) 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, with ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg, in treatment-naive participants infected with human immunodeficiency virus (HIV). The primary hypothesis is that doravirine, tenofovir, lamivudine q.d. is non-inferior to ATRIPLA™ q.d. as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48. This study has a total duration of 384 weeks, including a 96-week double-blind period and an additional 288-week open-label period.

Conditions

  • Human Immunodeficiency Virus (HIV)

Interventions

  • Doravirine, Tenofovir, LamivudineDrug

    One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

  • ATRIPLA™Drug

    One ATRIPLA™ tablet taken q.d. by mouth

  • PlaceboDrug

    Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48Time frame: Week 48
  2. Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)Time frame: Up to Week 48

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.